Eli Lilly’s (LLY) Alzheimer’s disease drug, donanemab, has been approved by India’s drug regulator and is expected to be launched within the next few months.
Donanemab is an amyloid-targeting therapy designed for individuals with mild cognitive impairment and those in the early stages of Alzheimer’s-related dementia.
The cost of the drug in India has not yet been finalized. In the United States, donanemab costs around $32,000 annually, equivalent to roughly Rs 28.34 lakh per year.
The final pricing in India is expected to depend on local manufacturing, import duties, and regulatory considerations.